Afluria Injection, Suspension
Product Images NDC 33332-025

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Afluria (NDC 33332-025). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Seqirus Pty Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Principal Display Panel – 5 mL Carton Label (Afl0h 0014 01)

Principal Display Panel – 5 mL Carton Label (Afl0h 0014 01)
This is the information of an influenza vaccine named afluria for the 2024-2025 formula. The vaccine is made from virus grown in embryonated chicken eggs and inactivated with beta-propiolactone. It contains the preservative thimerosal, with 24.5 mcg mercury per 0.5 mL dose and 12.25 mcg mercury per 0.25 mL dose. The vaccine does not contain natural rubber latex. It has trace amounts of polymysin, neomycin, and hydrocortisone from the early stages of manufacture.*
FDA Label Image

Principal Display Panel – 5 mL Vial Label (Afl0h 0014 02)

Principal Display Panel – 5 mL Vial Label (Afl0h 0014 02)
This text appears to be a description of a vaccine. It provides instructions for use, dosage information based on age, storage conditions, and manufacturing and distribution details. The vaccine is for intramuscular use only and specifies different doses for different age groups. It also mentions not to freeze the vaccine and to shake well before use. The manufacturer is Seqirus Pty Ltd located in Australia, while the distribution is handled by Seqirus USA Inc. located in the USA.*
FDA Label Image

Principal Display Panel – 0.5 mL Carton Label (Afl0h 0014 03)

Principal Display Panel – 0.5 mL Carton Label (Afl0h 0014 03)
This text provides detailed information about the influenza vaccine Afluria® for the 2024-2025 season. It includes the specific strains of influenza virus contained in the vaccine, dosage information, storage instructions, manufacturing process, and contact details for the manufacturer. The vaccine is prepared from virus grown in chicken eggs and inactivated with beta-propiolactone. It does not contain preservatives or natural rubber latex. The packaging includes 10 pre-filled syringes, each with a 0.5 mL dose, and is intended for intramuscular use in individuals aged 3 years and older. It is essential to store the vaccine between 2 - 8°C and protect it from light.*
FDA Label Image

Principal Display Panel – 0.5 mL Vial Label (Afl0h 0014 04)

Principal Display Panel – 0.5 mL Vial Label (Afl0h 0014 04)
This text appears to be a label or information from a medical product. It mentions a 0.5 mL dosage of something called "Ronly" intended for use in children aged 3 years and older. The product is manufactured by Seqirus Pty Ltd in Parkville, Australia. It includes a US license number and a lot number "Bp." Contact information is also provided with a phone number.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.